1. Are sarcopenia and myosteatosis in elderly patients with pelvic ring injury related to mortality, physical functioning and quality of life?
- Author
-
Sven H van Helden, Hester Banierink, Frank F A IJpma, Julia J C Bombach, Alain R. Viddeleer, Kaj Ten Duis, Erik Heineman, Robert J Nijveldt, Inge H. F. Reininga, Lifelong Learning, Education & Assessment Research Network (LEARN), Groningen Institute for Organ Transplantation (GIOT), Extremities Pain and Disability (EXPAND), Public Health Research (PHR), and Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE)
- Subjects
Quality of life ,medicine.medical_specialty ,Myosteatosis ,Sarcopenia ,Survival ,Article ,Pelvic ring injury ,Physical functioning ,Pelvic ring ,Internal medicine ,medicine ,In patient ,Survival analysis ,business.industry ,Mortality rate ,Retrospective cohort study ,General Medicine ,medicine.disease ,musculoskeletal system ,body regions ,Medicine ,business ,human activities - Abstract
The purpose of this study was to evaluate the prevalence of sarcopenia and/or myosteatosis in elderly patients with pelvic ring injuries and their influence on mortality, patient-perceived physical functioning and quality of life (QoL). A multicenter retrospective cohort study was conducted including elderly patients aged ≥ 65 treated for a pelvic ring injury. Cross-sectional computed tomography (CT) muscle measurements were obtained to determine the presence of sarcopenia and/or myosteatosis. Kaplan–Meier analysis was used for survival analysis, and Cox proportional hazards regression analysis was used to determine risk factors for mortality. Patient-reported outcome measures for physical functioning (SMFA) and QoL (EQ-5D) were used. Multivariable linear regression analyses were used to determine the effect of sarcopenia and myosteatosis on patient-perceived physical functioning and QoL. Data to determine sarcopenia and myosteatosis were available for 199 patients, with a mean follow-up of 2.4 ± 2.2 years: 66 patients (33%) were diagnosed with sarcopenia and 65 (32%) with myosteatosis, while 30 of them (15%) had both. Mortality rates in patients at 1 and 3 years without sarcopenia and myosteatosis were 13% and 21%, compared to 11% and 36% in patients with sarcopenia, 17% and 31% in patients with myosteatosis and 27% and 43% in patients with both. Higher age at the time of injury and a higher Charlson Comorbidity Index (CCI) were independent risk factors for mortality. Patient-reported mental and emotional problems were significantly increased in patients with sarcopenia.
- Published
- 2021